Inovio Pharmaceuticals
NYSE/NASDAQ:INOPharmaPlymouth, Pennsylvania, United States · Est. 1998 · 300 employees
Inovio Pharmaceuticals is a biotechnology company developing DNA-based immunotherapies and vaccines for cancer and infectious diseases.
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
2
Indications↗
Distinct diseases across all programs
28
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 21
Phase 11
By Therapeutic Area
top 1
Oncology
150%
R&D Momentum
12/100
Pipeline Velocity
0/100
Trial Completion Rate
92/100
Pipeline Concentration
50/100
Pipeline Freshness
17/100
Strategic Signals
- ↗Active in Oncology but thin pipeline — potential licensing opportunity
Activity
Key Events
Sep 3, 2026TrialAn Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Aug 12, 20268-K8-K
Jul 31, 20268-K8-K
Jul 29, 20268-K8-K
May 20, 20268-KINOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Oct 1, 2022TrialSafety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
Jun 21, 2021TrialSafety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Jan 27, 2021TrialDose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
4 more events
Nov 30, 2020TrialSafety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Jun 15, 2020TrialINO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Apr 3, 2020TrialSafety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
May 9, 2019TrialSafety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
Details
Company Info
Company Overview
$150.0M
Mkt Cap
$40.6M
Revenue
$65.8M
Cash
CEOPeter Lis
Founded1998
Employees300
HQPlymouth, Pennsylvania, United States
ExchangeNYSE/NASDAQ:INO
Websiteinovio.com
LinkedInCompany Page
Therapeutic Focus
OtherOncology
Recent SEC Filings
8-KAug 12, 2026
8-K
8-KJul 31, 2026
8-K
8-KJul 29, 2026
8-K
8-KMay 20, 2026
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Unknown / Other
Oncology
Glioblastoma
INO-5401Phase 2
Unknown / Other
BRCA1/2 Mutation
INO-5401Phase 1
Regulatory
Regulatory Timeline
20264 events
SECAug 12
8-K
Accession: 0001055726-26-000024
SECJul 31
8-K
Accession: 0001193125-26-326785
SECJul 29
8-K
Accession: 0001193125-26-323628
SECMay 20
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Accession: 001-14888
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)